Designed to evaluate the safety, effectiveness, and tolerability of a study drug compared with standard‑of‑care treatment in adults with primary membranous nephropathy.
Be between 18 and 79 years of age
Have a confirmed diagnosis of primary membranous nephropathy, established by:
A renal biopsy performed at screening or within 5 years prior to screening,
OR
Positive disease specific biomarker testing
Demonstrate nephrotic‑range proteinuria at screening
Be receiving stable supportive therapy prior to screening
Have clinical documentation indicating active disease, including evidence of disease activity prior to screening
Secondary causes of membranous nephropathy, including but not limited to autoimmune conditions, infections, and malignancies
Advanced kidney disease, including current dialysis, prior kidney transplant, and planned kidney transplantation during the study period
A significant decline in kidney function prior to screening
Kidney function glomerular filtration rate (eGFR) < 40 mL at screening
Certain clinically significant cardiovascular, infectious, immunologic, or systemic conditions that may increase risk or interfere with study participation
A history of specific infections or immune‑related conditions
Other eligibility criteria apply and will be evaluated by a principal investigator.
The MOMENT study includes a 2-year randomized controlled period (RCP) and a 1-year safety follow-up period.
Participants are randomized into study drug or standard-of-care medication. There is a 67% chance of receiving the study drug.
There is an optional one-year long-term extension (LTE) for eligible participants who complete the RCP. The extension period allows for continued evaluation of longer-term safety and disease-related outcomes. During this time, the standard-of-care medication is stopped and all eligible participants in the standard of care arm will receive the study drug. Participants who previously received the study drug will continue to receive the study drug only if they relapse during the LTE.
By enrolling in this study, patients may receive:
Study-related visits with a clinical research study team
Study required procedures and the study drug provided at no cost to qualified individuals
Reasonable reimbursement for travel and parking
Be randomized to receive either the study drug or standard-of-care medication.
Visit the study team up to 18 times during the study which lasts around 3 years including screening, treatment, and safety-follow up.
Participants who complete the treatment period may be able to take part in an optional one-year long-term extension (LTE) study.
If you have a patient who might be interested and potentially eligible for this study, you can:
Complete the "Contact PatientWing" form below. PatientWing will contact you and discuss how your patient can get involved.
Share this study directly with your patient so they can apply on their own. Provide them with this website so they can read about the study and fill out a questionnaire.
If you have a patient who may be eligible, we would love to speak with you! Please submit the information below so our team can reach out. There is no obligation to you or your patient by submitting this form.
